DENKHAUS DONALD A sold (to issuer) $15.7M of CPRX
DENKHAUS DONALD A sold (to issuer) 498,773 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($15.71M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s $15.71M sale at $31.50 with post-transaction holdings of 0 shares; this can influence sentiment but does not change fundamentals in the text.
Market read
Traders may monitor CPRX for sentiment effects from a large insider sale, but the filing provides no new business or clinical catalyst.
What to watch
No 10b5-1 plan is cited, but the filing also lacks context on tax, diversification, or compensation mechanics; without that, interpretation risk is high.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals, Inc.
Ticker impact
Catalyst Pharmaceuticals director Donald A Denkhaus sold 498,773 shares to the issuer at $31.50 on 2026-07-15, totaling $15.71M, per Form 4.
Likely limited immediate price impact; any effect would be sentiment-driven rather than fundamental.
The filing is a primary SEC Form 4 disclosure with transaction size and price, but it does not provide new operational or guidance information.
Market effects
No direct sector read-across; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
A sale to the issuer can be part of routine liquidity or structured transactions, so it may not signal reduced confidence.
Key entities
- issuerCATALYST PHARMACEUTICALS, INC.
CPRX, subject of the Form 4 insider transaction disclosure.
- insiderDENKHAUS DONALD A
Director who sold 498,773 shares to the issuer at $31.50 on 2026-07-15.